Details of the Drug Reposition

General Information of This Drug (ID: DMJRD7A)

Drug Name
GSK3326595   DMJRD7A
Synonyms
JLCCNYVTIWRPIZ-NRFANRHFSA-N; 1616392-22-3; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide; SCHEMBL15825290; MolPort-044-813-754; BDBM178166; AKOS030528008; ZINC220119494; CS-6451; AS-53150; HY-101563; GSK3326595(EPZ015938); US9675614, 208; (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04676516) A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer (OTT-19-06). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)